[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650213":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":24,"armGroups":33,"interventions":46,"overallOfficials":55,"centralContacts":60,"locations":66,"responsibleParty":83,"collaborators":24,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":24,"eligibilityCriteria":92,"healthyVolunteers":89,"sex":93,"minAge":94,"maxAge":24,"enrollmentInfo":95,"targetDuration":24,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":24,"overallStatus":69,"whyStopped":24,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Yarmook Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":24},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Maximum Mouth Opening (MMO)","Inter-incisal distance measured in millimeters using a digital caliper or standard ruler.","Up to 12 weeks postoperatively (evaluated at baseline, 2, 4, 8, and 12 weeks)",{"measure":14,"description":15,"timeFrame":12},"Pain intensity","Measured using a 0-10 pain numerical rating scale , where 0 equals no pain and 10 equals the worst pain possible.\n\nThe score indicates the degree of pain experienced by the patient by the patient at the baseline evaluation. Minimum score is 0, and the maximum score is 10.\n\nDuring the follow-up visits , decreasing pain score indicates better outcome, while increasing pain score indicates worse outcome.",{"measure":17,"description":18,"timeFrame":12},"Presence or Absence of Joint Sounds","Clinical examination evaluating the TMJ for joint sounds such as clicking, popping noise, or crepitus.",[20],{"measure":21,"description":22,"timeFrame":23},"Patient Satisfaction","Patient Satisfaction evaluated using the 5-point Likert-like scale ranging from the minimum score: 1 (very dissatisfied) to the maximum score: 5 (very satisfied), where higher scores indicate a better outcome.","Recorded at the final 12-week follow-up.",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":24,"primaryPurpose":28,"observationalModel":24,"timePerspective":24,"maskingInfo":29},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":30,"maskingDescription":24,"whoMasked":31},"SINGLE",[32],"PARTICIPANT",[34,40],{"label":35,"type":36,"description":37,"interventionNames":38},"Meloxicam","ACTIVE_COMPARATOR","Arthrocentesis with ringer lactate solution and meloxicam injection",[39],"Drug: Arthrocentesis with ringer lactate solution and meloxicam injection",{"label":41,"type":42,"description":43,"interventionNames":44},"Control","SHAM_COMPARATOR","Arthrocentesis with ringer lactate solution only",[45],"Drug: Arthrocentesis with ringer lactate solution",[47,51],{"type":48,"name":37,"description":49,"armGroupLabels":50,"otherNames":24},"DRUG","Intra-articular injection of 1ml of meloxical after TMJ arthrocentesis",[35],{"type":48,"name":52,"description":53,"armGroupLabels":54,"otherNames":24},"Arthrocentesis with ringer lactate solution","Arthrocentesis of the TMJ with ringer lactate only",[41],[56],{"name":57,"affiliation":58,"role":59},"Salwan Yousif Bede, B.D.S, F.I.B.M.S","Iraqi board for medical specialities","STUDY_DIRECTOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":24,"email":65},"Hussein Mohammed Ridha, B.D.S","CONTACT","009647706409168","hussein.mohammad@rocketmail.com",[67],{"facility":68,"status":69,"city":70,"state":24,"zip":24,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"Al-Yarmook teaching hospital","RECRUITING","Baghdad","Iraq","IQ",{"type":74,"coordinates":75},"Point",[76,77],44.40088,33.34058,{"lat":77,"lon":76},[80,81],{"name":62,"role":63,"phone":64,"phoneExt":24,"email":65},{"name":62,"role":82,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"type":84,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Hussein Mohammed Ridha","Principal investigator","100650213","clinical-effectiveness-of-combined-arthrocentesis-with-intra-articular-injection-of-meloxicam-in-treatment-of-temporomandibular-joint-internal-derangement-100650213",false,"NCT07743684","Clinical Effectiveness of Combined Arthrocentesis With Intra-articular Injection of Meloxicam in Treatment of Temporomandibular Joint Internal Derangement","Inclusion Criteria:\n\n* Adult patients \\>= 18 years diagnosed clinically with unilateral TMJ internal derangement with or without reduction, based on the Diagnostic Criteria for Temporomandibular Disorders (DC\u002FTMD).\n* Failure of conservative therapy (splint therapy, physiotherapy) for at least 1 month.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with bilateral TMJ internal derangement.\n* History of TMJ surgery or major trauma on the affected side.\n* Presence of rheumatic disease.\n* Severe degenerative joint disease.\n* Active infection around the TMJ.\n* Known bleeding disorders or patients on anticoagulant therapy.\n* Pregnancy or lactation.\n* Allergy to Meloxicam or its components.\n* Received intra-articular injections (corticosteroids, hyaluronic acid) in the TMJ within at least 3 months.","FEMALE","18 Years",{"count":96,"type":97},50,"ESTIMATED","INTERVENTIONAL",[100],"NA","This randomized controlled clinical study is designed to evaluate the clinical effectiveness of combining temporomandibular joint (TMJ) arthrocentesis with a single intra-articular injection of meloxicam in patients suffering from TMJ internal derangement.\n\nTemporomandibular disorders (TMD) are common conditions causing pain, restricted jaw movement, and joint sounds, which can significantly impair patients' quality of life. While conventional treatments include conservative approaches and arthrocentesis alone, finding optimal therapeutic protocols remains crucial for refractory cases.\n\nA total of 50 adult patients diagnosed with unilateral TMJ internal derangement (with or without reduction) who have failed at least one month of conservative therapy will be enrolled and randomly allocated into two equal groups:\n\nStudy Group: Will undergo joint arthrocentesis followed by a single intra-articular injection of meloxicam (15 mg \u002F 1.5 mL).\n\nControl Group: Will undergo joint arthrocentesis alone using Ringer's lactate solution.\n\nPatients will be evaluated across a 12-week postoperative period (at 2, 4, 8, and 12 weeks) to assess primary and secondary outcomes, including pain intensity (measured via a Numerical Rating Scale), maximum mouth opening (inter-incisal distance in millimeters), joint sounds (clicking, popping, or crepitus), and overall patient satisfaction. The findings aim to establish whether adding an intra-articular non-steroidal anti-inflammatory drug (NSAID) enhances the therapeutic benefits of standard TMJ arthrocentesis.",[103],"Temporomandibular Joint Internal Derangement","2026-08-03",{"date":106,"type":107},"2026-08-06","ACTUAL",{"date":109,"type":107},"2026-01-01",{"date":111,"type":97},"2027-10",{"name":85,"class":6},1]